Browse the evidence

Excess adiposity (BMI ≥30) is a causal risk factor for gastrointestinal cancers, increasing incidence and mortality through endocrine, inflammatory, and mechanical pathways.

Maintain a healthy weight to reduce your risk of gastrointestinal cancers. If you are overweight, consult your doctor about structured weight loss strategies, as obesity increases cancer risk and complicates surgical outcomes.

Semaglutide significantly reduces the risk of atrial fibrillation (AF) and sinus node dysfunction in patients with overweight or obesity.

If you have overweight or obesity and are concerned about heart rhythm issues like atrial fibrillation, semaglutide therapy (up to 2.4 mg) has been shown in large studies to significantly lower that risk. This benefit appears particularly strong in patients over 60 and those treated for more than a year.

Semaglutide significantly reduces the risk of acute myocardial infarction and angina pectoris in patients with overweight or obesity, with greater efficacy observed in patients over 60 years and those treated for more than 52 weeks.

For patients with overweight or obesity, semaglutide (up to 2.4 mg) significantly lowers the risk of heart attacks and angina. This benefit is particularly pronounced in patients over 60 years old and those who maintain treatment for more than one year, suggesting that long-term adherence is key to maximizing cardiovascular protection.

Akkermansia muciniphila supplementation in obese humans leads to greater weight loss and decreased plasma LPS levels compared to placebo, suggesting a direct microbiome-based therapy for obesity.

Akkermansia muciniphila is a specific gut bacterium that has shown promise in clinical trials for aiding weight loss in obese individuals. While not yet a formal recommendation, consuming foods that support this bacterium (like polyphenols) may be beneficial. Consult a healthcare provider before considering specific supplementation.

GLP-1 receptor agonists (GLP-1RAs) improve lipid profiles (lowering triglycerides, LDL-C, and total cholesterol, and raising HDL-C) in patients with type 2 diabetes and obesity, but these lipid-lowering effects are likely a modest contributor to their overall cardiovascular benefit.

GLP-1 medications like semaglutide and tirzepatide do improve your cholesterol and triglyceride levels, often significantly. However, their main heart-protective power comes from helping you lose weight, control blood sugar, and reduce inflammation, rather than just fixing your lipid numbers. You should still monitor your lipids, but don't expect these drugs to replace statins solely for lipid management.

Semaglutide reduces cardiovascular risk (MACE) and improves lipid profiles and blood pressure in patients with type 2 diabetes, independent of weight loss.

For patients with Type 2 Diabetes and high cardiovascular risk, semaglutide offers significant protection against major adverse cardiovascular events (heart attack, stroke, cardiovascular death) and slows kidney disease progression. It also modestly lowers blood pressure and improves lipid profiles through mechanisms independent of weight loss.

GLP-1 receptor agonists (semaglutide) and dual GLP-1/GIP agonists (tirzepatide) significantly improve cardiovascular outcomes and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, though they carry a risk of lean mass loss.

If you have HFpEF and obesity, GLP-1/GIP medications like semaglutide or tirzepatide can significantly improve your heart health, symptoms, and quality of life. To counteract potential muscle loss, you must combine these medications with resistance training and high protein intake. Discuss these options with your cardiologist, as they are increasingly recognized as effective treatments for this specific heart condition.

Tirzepatide reduces liver fat content and visceral adipose tissue in patients with Type 2 Diabetes.

If you have Type 2 Diabetes and are concerned about liver health, tirzepatide not only helps control blood sugar and weight but also significantly reduces liver fat, which is beneficial for overall metabolic health.

GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) and renal events compared to placebo, demonstrating cardiovascular and renal benefits beyond glycemic control.

For patients with Type 2 Diabetes, GLP-1 medications offer protection for the heart and kidneys, reducing the risk of major cardiovascular events and kidney disease progression, independent of their weight loss effects.

Resmetirom (80-100 mg daily) significantly improves MASH resolution and fibrosis regression in patients with F2-F3 fibrosis compared to placebo.

If you have moderate-to-advanced liver scarring from MASH, resmetirom is the first approved drug to help reverse it. Take 80mg or 100mg daily. Expect possible mild stomach issues, but serious risks are low. This targets the root hormonal imbalance driving liver fat.

GLP-1 receptor agonists (e.g., Semaglutide) improve MASH indirectly through weight loss and improved insulin resistance, as the liver lacks direct GLP-1 receptors.

GLP-1 drugs like Semaglutide help MASH by making you lose weight and improving insulin sensitivity, not by acting directly on the liver. They are approved for obesity and diabetes and show strong benefits for liver health through these indirect pathways.

GLP-1 receptor agonists (specifically liraglutide 3 mg/day) produce significant weight loss (8% mean reduction) and improve cardiovascular risk factors in obese and type 2 diabetic patients, though they carry a high discontinuation rate due to gastrointestinal side effects.

Liraglutide 3 mg daily is a highly effective pharmacological tool for weight loss, particularly for those with obesity or type 2 diabetes. It works by mimicking a gut hormone to increase satiety and slow digestion. While effective, it requires daily injections and careful dose titration to manage nausea. It is not a magic bullet; lifestyle changes are still required, and the high side-effect profile means it is not suitable for everyone.

Daily supplementation with 300 mg of Palmitoylethanolamide (PEA) combined with 8 weeks of resistance training does not impair skeletal muscle hypertrophy gains compared to placebo.

If you are doing resistance training and need pain relief, 300mg of PEA daily (split into two doses) will not hurt your muscle growth. It is a safe alternative to NSAIDs like ibuprofen, which can sometimes blunt strength gains. Take one capsule before your workout and one before bed.

Metformin is effective for preventing type 2 diabetes in prediabetic women, with efficacy varying by menopausal stage and hormonal status.

If you are a woman with prediabetes, metformin is a proven tool to prevent type 2 diabetes, but its effectiveness depends heavily on your menopausal status. It works best for premenopausal women and those who have gone through natural menopause, rather than those who have had their ovaries removed. While lifestyle changes are the first step, metformin is particularly valuable for high-risk individuals (younger, higher BMI, history of gestational diabetes) where lifestyle changes alone may not be enough. Be prepared for potential gastrointestinal side effects, which often improve over time.

Dairy consumption is associated with a reduced risk of cardiovascular events, including hypertension and stroke, despite containing saturated fats, due to the presence of bioactive peptides and specific fatty acids.

You do not need to fear the saturated fat in dairy for your heart health. Current evidence suggests that consuming dairy, including its fat content, is associated with a lower risk of stroke and hypertension. Fermented dairy and low-fat options may offer specific blood pressure benefits. Focus on the overall nutritional profile rather than isolating saturated fat as a primary risk factor.

Tirzepatide improves insulin sensitivity by 65.7%, a significantly greater improvement than the 37.5% observed with semaglutide.

Tirzepatide works differently than semaglutide by targeting both GLP-1 and GIP receptors, which leads to a much larger improvement in how your body uses insulin (65.7% vs 37.5%). This enhanced insulin sensitivity contributes to better blood sugar control and greater weight loss.

Phentermine-Topiramate produces moderate weight loss (7.87-8.45%) and improves cardiometabolic risk factors, but carries higher risks of neuropsychiatric and cardiovascular side effects compared to GLP-1RAs.

Phentermine-Topiramate is an oral medication that produces moderate weight loss (approx 8%). It is less effective than GLP-1RAs and carries higher risks of side effects like anxiety, paresthesia, and cardiovascular issues. It is not recommended for patients with existing heart disease.

GLP-1 receptor agonists reduce systolic blood pressure by 1.7 to 10.6 mmHg compared to placebo, contributing to stroke risk reduction.

GLP-1 drugs can help lower blood pressure, which is a key factor in preventing stroke. This effect is seen across different drugs in this class, with some showing reductions of up to 10 mmHg.

GLP-1 receptor agonists reduce the risk of atrial fibrillation by approximately 42% compared to placebo, which is a significant risk factor for stroke.

Taking GLP-1 drugs may also lower your risk of developing atrial fibrillation, a heart rhythm problem that increases stroke risk. This is another way these drugs protect your brain and heart.

Genetically proxied GLP-1R-based multi-target agonists (GIPR/GLP-1R, GCGR/GLP-1R, and GCGR/GIPR/GLP-1R) causally reduce the risk of Metabolic dysfunction-associated steatotic liver disease (MASLD) and its complications, including liver cancer and cardiovascular disease, partly independent of weight loss.

Genetic evidence strongly supports that GLP-1-based therapies (like semaglutide or tirzepatide) reduce the risk of fatty liver disease and its complications (liver cancer, heart disease). This benefit appears to come from improving metabolic health (insulin sensitivity, lipids) directly, not just from losing weight. If you have MASLD, these medications are a promising therapeutic option to discuss with your doctor, regardless of your current weight loss progress.

Discontinuation of semaglutide leads to significant weight regain ('semaglutide rebound'), with studies showing approximately two-thirds of lost weight is regained within one year.

If you stop taking semaglutide, expect to regain about two-thirds of the weight you lost within a year. This 'rebound' effect is common. Plan for sustainable lifestyle changes or discuss long-term management strategies with your doctor before stopping.

GLP-1 receptor agonists (semaglutide, tirzepatide) and dual agonists produce significant weight loss (15-22.5%) but are associated with lean muscle mass loss and require long-term adherence.

GLP-1 drugs like semaglutide and tirzepatide are highly effective for weight loss (15-22%), but you must take them long-term to maintain results. They can cause muscle loss, so combine them with resistance training and high protein intake. Be aware of GI side effects and contraindications like thyroid cancer history.

Performing bariatric surgery (Roux-en-Y or sleeve gastrectomy) prior to abdominoplasty significantly reduces postoperative complications and improves long-term stability compared to abdominoplasty alone in patients with metabolic syndrome.

If you have significant excess abdominal skin and metabolic issues (high blood pressure, diabetes, or high cholesterol), do not rush into skin removal surgery. You must first lose weight through diet, medication (like GLP-1s), or bariatric surgery until your weight and metabolic markers are stable for at least 6-12 months. This sequence drastically lowers your risk of infection, blood clots, and poor scarring, and ensures the skin removal looks good long-term.

Initiation of GLP-1 receptor agonists in adults with obesity or type 2 diabetes is associated with a substantially reduced risk of all-cause mortality, with the survival benefit being more pronounced in patients under 65 years of age and those with cardiometabolic comorbidities.

If you have obesity or type 2 diabetes, starting a GLP-1 RA (like semaglutide or liraglutide) is strongly associated with living longer, especially if you are under 65 or have other heart/kidney risks. While there is a small, early risk of pancreatitis, the survival benefit is substantial. Discuss this risk-benefit profile with your doctor, particularly if you have a history of pancreatic issues.